Compare GLP & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLP | CMPS |
|---|---|---|
| Founded | 2005 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2005 | 2020 |
| Metric | GLP | CMPS |
|---|---|---|
| Price | $46.62 | $13.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $46.00 | $25.38 |
| AVG Volume (30 Days) | 44.3K | ★ 2.5M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.40% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,561,421,000.00 | N/A |
| Revenue This Year | $64.13 | N/A |
| Revenue Next Year | $11.74 | N/A |
| P/E Ratio | $23.28 | ★ N/A |
| Revenue Growth | ★ 8.14 | N/A |
| 52 Week Low | $39.58 | $4.88 |
| 52 Week High | $54.29 | $15.87 |
| Indicator | GLP | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 30.24 | 43.12 |
| Support Level | $45.65 | $12.95 |
| Resistance Level | $48.48 | $14.98 |
| Average True Range (ATR) | 1.29 | 0.77 |
| MACD | -0.59 | -0.21 |
| Stochastic Oscillator | 0.90 | 10.07 |
Global Partners LP is a limited partnership that acts as a midstream logistics and marketing company. It is mainly engaged in purchasing, selling, storing and logistics of transporting petroleum and related products. The company owns and operates and control terminal networks of refined petroleum products and renewable fuels in Massachusetts, Maine, Connecticut, Vermont, and other places. It distributes gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, natural gas and propane to wholesalers, retailers and commercial customers. The company operates through three segments i.e. Wholesale, Gasoline Distribution and Station Operations and Commercial. It generates maximum revenue from the GDSO segment.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.